CA3183825A1 - Bifunctional superkines and uses thereof - Google Patents

Bifunctional superkines and uses thereof

Info

Publication number
CA3183825A1
CA3183825A1 CA3183825A CA3183825A CA3183825A1 CA 3183825 A1 CA3183825 A1 CA 3183825A1 CA 3183825 A CA3183825 A CA 3183825A CA 3183825 A CA3183825 A CA 3183825A CA 3183825 A1 CA3183825 A1 CA 3183825A1
Authority
CA
Canada
Prior art keywords
seq
bispecific
cancer
mutein
cytokine fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183825A
Other languages
English (en)
French (fr)
Inventor
Fahar Merchant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicenna Therapeutics Inc
Original Assignee
Medicenna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicenna Therapeutics Inc filed Critical Medicenna Therapeutics Inc
Publication of CA3183825A1 publication Critical patent/CA3183825A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3183825A 2020-06-24 2021-06-24 Bifunctional superkines and uses thereof Pending CA3183825A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063043227P 2020-06-24 2020-06-24
US63/043,227 2020-06-24
US202063093724P 2020-10-19 2020-10-19
US63/093,724 2020-10-19
US202063094322P 2020-10-20 2020-10-20
US63/094,322 2020-10-20
US202163165600P 2021-03-24 2021-03-24
US202163165738P 2021-03-24 2021-03-24
US63/165,600 2021-03-24
US63/165,738 2021-03-24
PCT/CA2021/050872 WO2021258213A1 (en) 2020-06-24 2021-06-24 Bifunctional superkines and uses thereof

Publications (1)

Publication Number Publication Date
CA3183825A1 true CA3183825A1 (en) 2021-12-30

Family

ID=79282489

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183825A Pending CA3183825A1 (en) 2020-06-24 2021-06-24 Bifunctional superkines and uses thereof

Country Status (6)

Country Link
US (1) US20230365642A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172216A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023532273A (cg-RX-API-DMAC7.html)
CN (1) CN116390744A (cg-RX-API-DMAC7.html)
CA (1) CA3183825A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021258213A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015KN00329A (cg-RX-API-DMAC7.html) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−4受容体結合融合タンパク質及びその使用
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP7819944B2 (ja) * 2020-07-09 2026-02-25 ユーティレックス カンパニー リミテッド Il-2バリアント
US12702710B2 (en) 2020-10-12 2026-08-11 Medicenna Therapeutics Inc. Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
KR20250004954A (ko) * 2022-03-08 2025-01-09 메디세나 테라퓨틱스, 인크. Il-2, il-13, 및 il-4 시토킨 이작용성 분자의 용도 및 방법
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023248009A1 (en) * 2022-06-21 2023-12-28 Medicenna Therapeutics, Inc. Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
CN121816367A (zh) * 2023-06-27 2026-04-07 梅迪塞纳医疗股份有限公司 Il-2融合蛋白
EP4770754A1 (en) 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512194B2 (en) * 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
WO2019239213A2 (en) * 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2019232523A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
TW202128961A (zh) * 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用

Also Published As

Publication number Publication date
EP4172216A4 (en) 2024-12-04
US20230365642A1 (en) 2023-11-16
WO2021258213A1 (en) 2021-12-30
JP2026120639A (ja) 2026-07-22
EP4172216A1 (en) 2023-05-03
JP2023532273A (ja) 2023-07-27
CN116390744A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
US12338269B2 (en) IL-2 superagonists in combination with anti-PD-1 antibodies
US20230365642A1 (en) Bifunctional superkines and uses thereof
US11034763B2 (en) Flag tagged CD19-CAR-T cells
US20220347268A1 (en) Il-4r as a biomarker in cancer
CN109476749A (zh) 改良的过继性t细胞疗法
US12404497B2 (en) Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
WO2023248009A1 (en) Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
US20250387474A1 (en) Uses and methods for il-2, il-13, and il-4 cytokine bifunctional molecules
US20220177599A1 (en) Dual chimeric antigen receptor targeting epcam and icam-1
EP4735483A2 (en) Il-2 fusion proteins
WO2026015911A1 (en) Compositions and methods comprising epitopes and polypeptides
HK40030405B (en) Chimeric antigen receptor (car) binding to bcma, and uses thereof
HK40030405A (en) Chimeric antigen receptor (car) binding to bcma, and uses thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250619

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250826

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827